Notice2023-14704
Reorganization of the National Center for Emerging and Zoonotic Infectious Diseases
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
July 12, 2023
Issuing agencies
Health and Human Services DepartmentCenters for Disease Control and Prevention
Abstract
CDC has modified its structure. This notice announces the reorganization of the National Center for Emerging and Zoonotic Infectious Diseases (NCEZID). NCEZID reorganized to improve collaboration between science and public health programs within NCEZID as well as with our partners across and outside the agency, which will increase our public health impact.
Full Text
<html>
<head>
<title>Federal Register, Volume 88 Issue 132 (Wednesday, July 12, 2023)</title>
</head>
<body><pre>
[Federal Register Volume 88, Number 132 (Wednesday, July 12, 2023)]
[Notices]
[Pages 44318-44331]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2023-14704]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Reorganization of the National Center for Emerging and Zoonotic
Infectious Diseases
AGENCY: Centers for Disease Control and Prevention (CDC), the
Department of Health and Human Services (HHS).
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: CDC has modified its structure. This notice announces the
reorganization of the National Center for Emerging and Zoonotic
Infectious Diseases (NCEZID). NCEZID reorganized to improve
collaboration between science and public health programs within NCEZID
as well as with our partners across and outside the agency, which will
increase our public health impact.
DATES: This reorganization was approved by the Director of CDC on June
28, 2023.
FOR FURTHER INFORMATION CONTACT: Kimberly Thurmond, Office of the Chief
Operating Officer, Office of the Director, Centers for Disease Control
and Prevention, 1600 Clifton Road NE, MS TW-2, Atlanta, GA 30329.
Telephone 770-488-4401; Email: <a href="/cdn-cgi/l/email-protection#077562687560744764636429606871"><span class="__cf_email__" data-cfemail="82f0e7edf0e5f1c2e1e6e1ace5edf4">[email protected]</span></a>.
SUPPLEMENTARY INFORMATION: Part C (Centers for Disease Control and
Prevention) of the Statement of Organization, Functions, and
Delegations of Authority of the Department of Health and Human Services
(45 FR 67772-76, dated October 14, 1980, and corrected at 45 FR 69296,
October 20, 1980, as amended most recently at 88 FR 9290-9291, dated
February 13, 2023) is amended to reflect the reorganization of the
National Center for Emerging and Zoonotic Infectious Diseases, Centers
for Disease Control and Prevention. Specifically, the changes are as
follows:
I. Under Part C, Section C-B, Organization and Functions, insert
the following:
<bullet> National Center for Emerging and Zoonotic Infectious Diseases
(CR)
<bullet> Office of the Director (CR1)
<bullet> Division of Foodborne, Waterborne, and Environmental Diseases
(CRB)
<bullet> Office of the Director (CRB1)
<bullet> Enteric Diseases Epidemiology Branch (CRBB)
<bullet> Enteric Diseases Laboratory Branch (CRBC)
<bullet> Outbreak Response and Prevention Branch (CRBD)
<bullet> Waterborne Disease Prevention Branch (CRBE)
<bullet> Mycotic Diseases Branch (CRBG)
<bullet> Division of Global Migration Health (CRC)
<bullet> Office of the Director (CRC1)
<bullet> Travel Risk Assessment and Mitigation Branch (CRCB)
<bullet> Immigrant and Refugee Health Branch (CRCC)
<bullet> Travelers' Health Branch (CRCD)
<bullet> Port Health Protection Branch (CRCE)
<bullet> Southern Border Health and Migration Branch (CRCG)
<bullet> Division of Healthcare Quality Promotion (CRD)
<bullet> Office of the Director (CRD1)
<bullet> Antimicrobial Resistance Coordination and Strategy Unit
(CRD12)
<bullet> Immunization Safety Office (CRDB)
<bullet> Clinical and Environmental Microbiology Branch (CRDC)
<bullet> Prevention and Response Branch (CRDD)
<bullet> Surveillance Branch (CRDE)
<bullet> Epidemiology Research and Innovations Branch (CRDG)
<bullet> Healthcare Systems Strengthening, Resilience, and Training
Branch (CRDH)
<bullet> International Infection Control Branch (CRDJ)
<bullet> Medical Product Safety Branch (CRDK)
<bullet> Division of High-Consequence Pathogens and Pathology (CRE)
<bullet> Office of the Director (CRE1)
<bullet> Prion and Public Health Office (CRE12)
<bullet> Viral Special Pathogens Branch (CREB)
<bullet> Poxvirus and Rabies Branch (CREC)
<bullet> Infectious Diseases Pathology Branch (CRED)
<bullet> Chronic Viral Diseases Branch (CREE)
<bullet> Bacterial Special Pathogens Branch (CREG)
<bullet> Division of Infectious Disease Readiness and Innovation (CRG)
<bullet> Office of the Director (CRG1)
<bullet> Arctic Investigations Program (CRGB)
<bullet> Epidemiology Laboratory Capacity and Informatics Branch (CRGC)
<bullet> Rapid Response Research and Surveillance Branch (CRGD)
<bullet> Office of Advanced Molecular Detection (CRGE)
<bullet> Division of Core Laboratory Services and Response (CRH)
<bullet> Office of the Director (CRH1)
<bullet> Advanced Diagnostics and Biotechnologies Branch (CRHB)
<bullet> Comparative Medicine Branch (CRHB)
<bullet> Preparedness, Response, and Outbreak Services Branch (CRHD)
<bullet> Laboratory Products and Services Branch (CRHE)
<bullet> Division of Vector-Borne Diseases (CRJ)
<bullet> Office of the Director (CRJ1)
<bullet> Arboviral Diseases Branch (CRJB)
<bullet> Bacterial Diseases Branch (CRJC)
<bullet> Dengue Branch (CRJD)
<bullet> Rickettsial Zoonoses Branch (CRJE)
<bullet> Division of Parasitic Diseases and Malaria (CRK)
<bullet> Office of the Director (CRK1)
<bullet> Malaria Branch (CRKB)
<bullet> Parasitic Diseases Branch (CRKC)
<bullet> Entomology Branch (CRKD)
<bullet> Laboratory Science and Diagnostics Branch (CRKE)
II. Under Part C, Section C-B, Organization and Functions, retitle
the following organizational units:
<bullet> Division of Global Migration and Quarantine to Division of
Global Migration Health (CRC)
<bullet> Division of Scientific Resources to Division of Core
Laboratory Services and Response (CRH)
III. Under Part C, Section C-B, Organization and Functions, delete
the mission or functional statements for and replace with the
following:
National Center for Emerging and Zoonotic Infectious Diseases (CR).
The National Center for Emerging and Zoonotic Infectious Diseases
(NCEZID) saves lives through the prevention, early detection, and
control of infectious disease threats. In carrying out these
activities, NCEZID: (1) works collaboratively across CDC and with
external partners to conduct, coordinate, support, and evaluate public
health efforts to prevent and minimize morbidity and mortality due to
[[Page 44319]]
infectious diseases, promoting a One Health approach involving the
interface of animal, human, and environmental factors; (2) leads
agency-wide efforts in planning for and responding to infectious
disease outbreaks in the United States and around the world; (3)
develops, evaluates, and advances science, programs, management, and
operations toward meeting the agency's infectious disease-related
mission and goals and improving the agency's response readiness; (4)
conducts epidemiologic and laboratory science and applied research
aimed at identifying risk factors and disease burdens and developing
and implementing public health programs, practices, and policies for
infectious disease prevention and control including increasing health
equity; (5) works with domestic and global partners to provide
technical and subject matter expertise in responding to outbreaks and
in establishing, maintaining, and evaluating disease control and
prevention programs; (6) supports a broad range of cross-cutting and
collaborative programs aimed at enhancing response readiness and public
health capacity at the local, state, and national levels; (7) works to
improve the quality and safety of healthcare through efforts to reduce
healthcare associated infections and antimicrobial resistance and to
ensure the safety of medical products, including vaccines; (8) conducts
activities to improve the safety of food and water and reduce related
enteric illnesses; conducts activities to address diagnosis,
prevention, and control of vector-borne diseases, including malaria, in
the United States and globally; (9) administers a national public
health program to prevent U.S. importation and spread of infectious
diseases; (10) works with CDC colleagues and external partners to
improve public health preparedness at the local, state, and national
levels; and (11) works to increase public health prevention efforts for
populations at increased risk for infectious diseases.
Office of the Director (CR1). (1) provides leadership in
developing, prioritizing, advancing, and evaluating the Center's
science, programs, management, and operations toward meeting agency
mission and goals; (2) advises the CDC Director and Immediate Office of
the Director (IOD) on priority issues affecting the Center; (3)
identifies and facilitates synergies within NCEZID, across CDC, and
with external partners for enhancing infectious disease response
readiness and addressing emerging and zoonotic infectious diseases
domestically and globally; (4) enhances collaborations and partnerships
across multiple disciplines, including human and animal health; and
works to systematically reduce disparities related to emerging and
zoonotic infectious diseases; (5) serves as the focal point and
programmatic home for activities on One Health, an integrated approach
to optimizing human and animal health that considers the
interrelatedness among humans, animals, and their environments; (6)
builds and manages a portfolio of One Health activities, plans, and
accomplishments; (7) leads Center-wide enhancement of data systems to
support predictive data science and rapid sharing of information,
supported by modern information technology platforms and enterprise
services that facilitate CDC's public health mission; (8) provides
assay validation and surge testing support for outbreak response; (9)
provides foundation for design control for assay development and
supports compliance with agency quality plan; (10) maintains close
programmatic oversight of the Division of Healthcare Quality
Promotion's Antimicrobial Resistance Coordination and Strategy Unit and
the Division of Infectious Disease Readiness and Innovation's Office of
Advance Molecular Detection, assuring a direct line for communication
with the directors of those programs; (11) provides leadership,
guidance, and technical assistance on policy and communication issues
affecting the center; (12) serves as liaison with CDC counterparts,
CDC/IOD, other government agencies, and external partners on policy,
program, legislative, communication, and budgetary issues related to
NCEZID; (13) serves as the Designated Federal Official (DFO), provides
leadership for, and manages the infectious diseases Board of Scientific
Counselors, a chartered Federal advisory committee that advises on
strategies, goals and priorities for CDC's infectious disease programs
and research; (14) recruits and supports a strong, diverse Center-wide
workforce and builds leadership at the division and branch levels to
promote the integration of diversity into all aspects of the workforce;
(15) ensures program accountability, supporting achievement of
programmatic goals with measurable impact; (16) supports effective
administrative services for NCEZID as well as effective cross-cutting
scientific and program services for all CDC's infectious disease
national Centers; and (17) provides staffing and support for emergency
responses at program, division, Center, and agency levels.
Division of Foodborne, Waterborne, and Environmental Diseases
(CRB). The mission of the Division of Foodborne, Waterborne, and
Environmental Diseases (DFWED) is to improve public health nationally
and internationally through the prevention and control of disease,
disability, and death caused by foodborne, waterborne, other enteric,
and fungal infections. In carrying out its mission, DFWED: (1) develops
and leads national surveillance platforms and conducts surveillance,
investigations, and studies of foodborne bacterial diseases, waterborne
diseases, and mycotic diseases to determine the sources and develop
effective methods for diagnosis, prevention, and control; (2) conducts
or participates in clinical, field, and laboratory research to develop,
evaluate, and improve laboratory methodologies, materials, diagnostics,
and therapeutic practices used for environmental detection, diagnosis,
treatment, investigation, and control of foodborne and zoonotic
bacterial diseases, water, sanitation, and hygiene-related diseases,
and mycotic diseases, including those affected by changes in the
environment or climate; (3) conducts environmental microbiology
research activities at CDC through partnerships and external activities
to promote research on prevention and control of infectious disease
transmission from the environment to humans; (4) provides epidemiologic
consultation, upon request, to state and local health departments,
other Federal agencies, national and international health
organizations, and ministries of health; (5) provides reference/
diagnostic services for foodborne and zoonotic bacterial diseases,
waterborne bacterial and parasitic diseases, and mycotic diseases to
state and local health departments, other Federal agencies, and
national and international health organizations; (6) investigates
outbreaks, conducts surveillance, and engages in research studies
concerning the emergence and spread of antimicrobial resistant enteric
and mycotic pathogens across the One Health spectrum; (7) provides
scientific and technical assistance to other CDC components when the
work requires unique expertise or specialized equipment not available
in other components; (8) provides intramural and extramural technical
expertise and assistance in professional training and proficiency
testing activities; (9) serves as appropriately designated national and
international reference centers for
[[Page 44320]]
various foodborne bacterial diseases, waterborne bacterial and
parasitic diseases, and mycotic diseases; (10) develops clear health
promotion strategies, campaigns, and messages to promote prevention and
control, including strategies specifically aimed to improve the health
outcomes of populations at disproportionate risk of these diseases;
(11) coordinates with other Federal agencies and partners organizations
to prevent foodborne, waterborne, other enteric, and mycotic diseases;
(12) provides staffing and support for emergency responses at program,
division, Center, and agency levels; and (13) trains Epidemic
Intelligence Service (EIS) officers, fellows, students, staff, and
visiting scientists from the United States and abroad.
Office of the Director (CRB1). (1) directs and manages the programs
and activities of DFWED; (2) provides leadership and guidance on
policy, communication, prevention science, program planning and
development, program management, and operations; (3) coordinates or
assures coordination with the appropriate CDC and NCEZID offices on
administrative and program matters; (4) reviews, prepares, and
coordinates Congressional testimony and briefing documents related to
enteric and fungal diseases and analyzes programmatic and policy
implications of legislative proposals and analyzes programmatic and
policy implications of legislative proposals; (5) represents CDC and
NCEZID programs and prevention policies in meetings with governmental,
private, and international organizations; (6) advises CDC and NCEZID on
policy and communication matters concerning DFWED programs and
activities; (7) coordinates, advises, and conducts internal and
external communications activities for the division, including
communication research, public affairs, social media, and web; (8)
leads and manages consumer food safety education for the division,
including representing cross-cutting CDC consumer food safety education
efforts with governmental, private, and international organizations;
(9) provides statistical support across the division by developing
novel methods or adapting existing methods for assisting in outbreak
investigations, disease surveillance efforts, research studies, and
developing statistical acumen of staff; (10) coordinates the division's
data management and informatics efforts to align with division and
agency data and surveillance priorities; (11) facilitates the division
capacity-building program activities under the Epidemiology and
Laboratory Capacity (ELC) Cooperative Agreement including providing
guidance and technical assistance to state, local, and territorial
agencies about implementing foodborne, waterborne, and other enteric
disease surveillance and response activities; (12) supports the
development, implementation, and evaluation of model practices and
quality improvement initiatives associated with division's capacity
building activities; (13) defines and implements division-wide priority
prevention efforts; (14) collaborates with Federal agencies and
industry partners to support related external activities; (15) provides
oversight for CDC involvement in the World Health Organization (WHO)
International Food Safety Authorities Network and training in
foodborne, waterborne, and other enteric disease control and
prevention; (16) provides subject matter expertise on environmental
research, and promotes and coordinates related research activities at
CDC and with collaborative partners; (17) provides leadership in
preventing and controlling foodborne illness by coordinating related
activities within CDC and with other local, state, Federal, and
international organizations; (18) advises and supports the activities
related to development of long-term NCEZID and CDC strategies,
policies, and budgets for foodborne disease prevention activities; (19)
allocates and tracks resources, including interagency, within CDC for
foodborne disease surveillance, outbreak response, applied research,
education and training; (20) administers and tracks resources for
foodborne disease prevention and control activities of national
organizations representing state and local health departments; (21)
represents NCEZID and CDC programs and prevention policies in meetings
with governmental, non-governmental, private, and international
organizations, and (22) enhances interagency coordination and
collaboration of public health activities with the Food and Drug
Administration (FDA) and the U.S. Department of Agriculture, including
through interagency liaisons.
Enteric Diseases Epidemiology Branch (CRBB). (1) conducts
surveillance, investigation, analyses, and research on bacterial
enteric diseases and provides consultations to state and local health
departments, other Federal agencies, and national and international
health organizations on pathogens transmitted by food, water, and
contact with animals or their environments, and from one person to
another; (2) conducts surveillance for and analyses of summary data on
outbreaks of acute enteric illness in the United States; (3) devises
methods and conducts analyses to measure the burden of and trends in
bacterial enteric diseases, with a special focus on those transmitted
by food; (4) devises methods and conducts analyses to attribute
bacterial enteric illnesses to specific food categories; (5) as part of
the National Antimicrobial Resistance Monitoring System (NARMS),
conducts surveillance, investigation, analyses, and research on
antimicrobial resistance in bacterial enteric organisms, including
measurements of trends; (6) performs studies to determine risk factors
for, and host and etiologic agent factors related to, bacterial enteric
diseases; (7) coordinates and collaborates in national and
international enteric disease surveillance, training, and studies; (8)
coordinates the investigation and control of enteric diseases with
other CDC groups and with other U.S. Federal and local government
agencies, state health departments, and international health agencies;
(9) participates with other CDC groups, state health departments,
regulatory agencies, industry, and other groups in determining and
assessing the effectiveness of prevention strategies for acute
bacterial enteric diseases; (10) prepares and disseminates health
communication materials on the prevention of acute bacterial enteric
diseases and their long-term health effects; and (11) provides
information and expert advice to policy makers about bacterial enteric
diseases and their acute and long-term health effects.
Enteric Diseases Laboratory Branch (CRBC). (1) uses molecular
surveillance to identify problems and track trends in foodborne and
diarrheal diseases; (2) maintains expertise in microbiology, molecular
biology, immunology, and microbial pathogenesis of organisms that cause
foodborne and diarrheal diseases; (3) coordinates PulseNet, a network
of public health laboratories created to build capacity to identify,
investigate, and control health threats across the nation; (4) informs
outbreak investigations, other public health investigations, and
applied research to identify risk factors and improved prevention
strategies; (5) detects and characterizes bacterial enteric pathogens,
including Clostridium botulinum, that could be involved in
unintentional or bioterrorism events (6) conducts surveillance,
investigation, analyses, and research on antimicrobial resistance,
including managing the laboratory component of the NARMS at CDC; (7)
improves methods for and utilization of laboratory-based
[[Page 44321]]
surveillance; (8) uses laboratory and other data to guide control and
prevention strategies for foodborne and diarrheal illness; and (9)
partners with reference laboratories throughout the world to build
capacity for the diagnostic and molecular surveillance of foodborne
infections both domestically and internationally.
Outbreak Response and Prevention Branch (CRBD). (1) provides
epidemic aid, investigation, analysis, and consultation on foodborne
and zoonotic diseases outbreaks to state and local health departments,
other Federal agencies, and national and international health
organizations; (2) coordinates outbreak response activities within the
Enteric Diseases OutbreakNet, a national network of epidemiologists and
other public health officials who investigate outbreaks of foodborne,
zoonotic, waterborne, and other enteric illnesses in the United States;
(3) coordinates the investigation and control of enteric health
problems with other CDC groups, and within other U.S. Federal and local
government agencies, state health departments, and foreign health
agencies; (4) develops and evaluates prevention strategies for
foodborne and zoonotic diseases in consultation with regulatory
agencies, industry, and other health agencies; (5) develops, evaluates,
and supplies outbreak investigation tools and training materials for
state and local health departments; (6) supervises EIS field
investigations; (7) prepares and disseminates health communications
materials on the control and prevention of foodborne and zoonotic
disease outbreaks; and (8) provides information and expert advice to
policy-makers and regulatory authorities on the control and prevention
of foodborne and zoonotic disease outbreaks.
Waterborne Disease Prevention Branch (CRBE). (1) identifies,
tracks, and assesses risk factors, causes, and sources of water,
sanitation, and hygiene (WASH)-related illness cases and outbreaks; (2)
prepares for and responds to water-related emergencies and disease
outbreaks, provides assistance and capacity to state and local health
departments, other Federal agencies, national ministries of health, and
international health organizations; (3) develops appropriate sampling,
detection, tracking, and assessment methods for clinical, water, and
other environmental specimens; (4) develops and evaluates methods for
pathogen inactivation or removal; (5) provides diagnostic and clinical
consultation services for waterborne protozoan parasitic infections;
(6) develops, monitors, and evaluates existing and new public health
interventions; (7) develops clear health promotion strategies,
campaigns, and messages; (8) provides partners with technical and
capacity building assistance; (9) leads national surveillance systems
for WASH-related diseases and outbreaks; (10) collects data for public
health policy development and evaluation; and (11) coordinates with
Federal agencies and partner organizations on WASH-related disease
prevention efforts.
Mycotic Diseases Branch (CRBG). (1) provides epidemic aid,
surveillance, laboratory support, and consultation on the prevention
and control of established, emerging, reemerging, and opportunistic
mycotic (i.e., fungal) diseases; (2) provides reference and diagnostic
support for agents causing mycotic diseases and for the identification
of unknown mycotic isolates associated with human disease; (3)
coordinates and collaborates with state and local health departments,
other Federal agencies, and national and international health
organizations in order to detect, respond to, and prevent mycotic
diseases; (4) evaluates methods for the detection of established,
emerging, reemerging, and opportunistic mycotic diseases; (5) develops,
implements, and evaluates prevention and control strategies for these
diseases; (6) collaborates with other CDC Centers, Institute, and
Offices (CIOs), NCEZID divisions, state and Federal agencies in
addressing reemerging mycotic diseases; and (7) provides information
and expert advice to policy-makers and regulatory authorities on the
control and prevention of mycotic diseases outbreaks
Division of Global Migration Health (CRC). The mission of the
Division of Global Migration Health (DGMH) is to reduce morbidity and
mortality among immigrants, refugees, travelers, expatriates, and other
globally mobile populations, and to prevent the introduction,
transmission, and spread of communicable diseases through regulation,
science, research, emergency preparedness, and response. In carrying
out its mission, DGMH: (1) administers a national public health program
to protect the United States against the introduction of diseases from
foreign countries and the transmission of communicable disease between
states; (2) administers an overseas program for the medical examination
of immigrants, refugees, and as necessary, other migrant populations
applying for legal entry to the United States, to identify those with
inadmissible health conditions that would pose a threat to public
health and impose a burden on public health and hospital facilities;
(3) conducts public health surveillance, research, and prevention
programs to detect, prevent, and minimize morbidity and mortality among
globally mobile populations entering and leaving the U.S.; (4)
maintains liaison with other Federal agencies, state and local health
departments, and other partners, and provides information on global
migration and public health threats related to travel and migration and
on requirements under CDC's authority and International Health
Regulations (IHR); (5) serves as a liaison with international health
organizations and participates in the development of international
agreements affecting the health of globally mobile populations; (6)
develops, enforces, and evaluates policies necessary for implementation
of Federal quarantine authorities protecting the public's health
through actions taken at ports of entry (POE) or for travelers entering
or traveling interstate within the United States or of CDC-regulated
items; (7) conducts studies to provide new information about health
hazards abroad, measures for their prevention, and the potential threat
of disease introduction into the United States, and develops
educational materials for travelers and travel medicine providers; (8)
provides logistic support to other programs of the CDC in the
distribution of requested therapeutics available under CDC-maintained
investigational new drug protocols and movement of biological specimens
through U.S. POE; (9) advances preparedness and response for public
health emergencies and threats associated with the introduction of
diseases from foreign countries and the transmission of communicable
disease between states; and (10) provides staffing and support for
emergency responses at program, division, Center, and agency levels.
Office of the Director (CRC1). (1) manages, directs, and
coordinates the strategies and activities of the division; (2) provides
scientific leadership including oversight of scientific integrity and
quality and health equity; (3) directs development of division policy,
program planning, and partnerships, and implements regulatory
responsibilities,; (4) identifies needs and resources for new
initiatives and assigns responsibilities for their development; (5)
coordinates liaison with international health organizations, other
Federal agencies, state and local health departments, and interested
industries on matters related to travel and migration; (6) provides
support for the administration of interstate and foreign quarantine
regulations and compliance with the IHR; (7)
[[Page 44322]]
coordinates division emergency preparedness, readiness, response
guidance and operations for international and domestic public health
incidents; (8) reviews and evaluates all administrative services for
headquarters, border health stations, and overseas offices, and
provides policy procedures and guidance on such matters; (9) provides
communication strategy and product development; (10) coordinates
division strategic workforce and Diversity, Equity, Inclusion,
Belonging, and Accessibility objectives, and (11) supports science with
data, advanced analytics, and technology.
Division of Healthcare Quality Promotion (CRD). The mission of the
Division of Healthcare Quality Promotion (DHQP) is to protect patients;
protect healthcare personnel; and promote safety, quality,
preparedness, resilience, equity, and value in both national and
international healthcare delivery systems. In carrying out its mission,
DHQP: (1) measures, validates, interprets, and responds to data
relevant to healthcare-associated infections (HAI); antimicrobial use
and resistant infections; sepsis, adverse drug events; blood, organ and
tissue safety; and immunization safety; environmental hygiene; and
other related topics and adverse events in healthcare settings; (2)
leads responses to, investigates and addresses emerging problems and
infections, antimicrobial resistance, and related adverse events among
patients and healthcare personnel, and in communities affected by
antimicrobial resistant or healthcare-associated pathogens; (3)
develops and maintains the National Healthcare Safety Network (NHSN), a
national system for monitoring healthcare-associated infections,
antimicrobial use and resistance, measuring healthcare outcomes and
processes, and monitoring healthcare personnel vaccination and selected
health measures in healthcare facilities; (4) assesses local, regional,
national scope and burden of infections caused by antimicrobial
resistant-bacteria in the United States and internationally, through
surveillance and special studies, review of healthcare data sets, and
laboratory surveillance programs; (5) conducts epidemiologic, and basic
and applied laboratory research to identify new strategies to detect,
track, and prevent infections/antimicrobial resistance, and related
adverse events or medical errors, including those associated with the
safety of medical or surgical procedures, indwelling medical devices,
medical product contamination, dialysis, healthcare environments and
water; (6) collaborates with academic, industry, and government
partners to design, develop, and evaluate new public health approaches
to monitoring infections and the efficacy of interventions for
preventing infections, improving antibiotic use, and reducing
antimicrobial resistance, and related adverse events or medical errors;
(7) develops and disseminates evidence-based guidelines and
recommendations to prevent and control HAI, antimicrobial resistance,
and related adverse events in healthcare settings; (8) collaborates
with Federal, state, and local public health and private partners to
promote nationwide implementation of CDC Guidelines and other evidence-
based interventions to prevent HAI, antimicrobial resistance, and
related adverse events or medical errors among patients and healthcare
personnel; (9) evaluates the impact of evidence-based recommendations
and interventions across the spectrum of healthcare delivery sites;
(10) serves as the DFO for, provides technical support to, and manages
the Healthcare Infection Control Practices Advisory Committee (HICPAC);
(11) serves as the National Reference Laboratory for the identification
and antimicrobial susceptibility testing of staphylococci, anaerobic
bacteria, non-tuberculous mycobacteria, and gram-negative bacilli
causing healthcare-associated and related community infections; (12)
serves as the technical reference laboratory for detection and
characterization of other pathogens related to healthcare, and for
characterizing the contribution of the healthcare environment to HAI
and antimicrobial resistant infections, and impacts on surrounding
communities; (13) serves as a global resource for healthcare associated
infections, antimicrobial resistance, and environmental hygiene; (14)
coordinates guidance and research related to infection control and
antimicrobial resistance across the agency and with national and
international partners; (15) monitors vaccine safety and conducts
research to evaluate the safety of available and new vaccines; (16)
trains EIS Officers, Laboratory Leadership Fellows, and other trainees
in national public health; (17) coordinates agency-wide antimicrobial
resistance activities and investments; (18) works in a national
leadership capacity with public and private organizations to enhance
antimicrobial resistance prevention and control, surveillance and
response, and applied research; (19) coordinates and provides expertise
and investigative capacity for blood, organ, and other tissue safety
issues at CDC; (20) provides expertise and assistance to HHS and other
Federal agencies and global partners on efforts and activities related
to safe healthcare; (21) leads international healthcare quality
improvement and infection control efforts; (22) represents CDC in
international convenings related to healthcare quality and
antimicrobial resistance; (23) leads the partnerships between CDC and
other HHS counterparts on healthcare quality topics and activities;
(24) builds and supports HAI and antimicrobial resistance prevention
and control efforts of state and local public health entities and
laboratories; (25) delivers tailored consultation and training content
to healthcare facilities and personnel across the spectrum of US
healthcare; (26) assesses and improves safety of healthcare personnel
related to HAI and related threats; (27) assesses and improves equity
in healthcare delivery; (28) improves the effectiveness and safety of
healthcare practices, protocols, systems, and equipment use related to
infection prevention and control; (29) coordinates infection prevention
and control content for non-pharmaceutical interventions across
community settings; and (30) provides staffing and support for
emergency responses at program, division, Center, and agency levels.
Office of the Director (CRD1). (1) manages, directs, and
coordinates the activities of DHQP; (2) provides strategic direction
and coordination of communication, policy, and partnership programs and
activities; (3) provides leadership and guidance on policy impacting
patient and healthcare safety; (4) leads targeted patient safety
communication campaigns coordinated with release of CDC surveillance
data, infection control guidelines, national and international
healthcare related response activities, research and policy
publications, and prevention tools; (5) fosters strategic partnerships
with clinical professional organizations, academic entities, research
institutes, healthcare systems, consumers and other partners to
eliminate HAI and related adverse events, prevent sepsis, combat
antimicrobial resistance, improve health system equity and resilience;
(6) leads and ensures accuracy of DHQP content for communication/media
outreach, crisis communications, CDC web content, and content for
social media platforms; (7) works with Federal agencies, international
organizations, and other partners on activities related to safe
[[Page 44323]]
healthcare; (8) monitors, supports, and connects state activities to
track and prevent HAI and antimicrobial resistance; (9) identifies
consensus goals and implements portfolio management across DHQP
programs to meet those goals; (10) oversees the quality of DHQP
research and scientific activities and identifies knowledge gaps; (11)
provides leadership and strategic planning for program growth and
development; (12) provides administrative and program services,
managerial and operations support, and coordination with the
appropriate CIOs and CDC staff offices on administrative and program
matters including budget formulation and execution and human resource
management; (13) oversees the coordination of Federal and state
programs and new initiatives to prevent HAI, immunization safety, other
healthcare adverse events, and antimicrobial resistance; (14)
interprets general program and administrative policy directives for
implications on management and execution of DHQP programs; (15) serves
as lead and primary contact and liaison with relevant CDC staff offices
for procurement requirements; (16) provides management and coordination
for DHQP-occupied space and facilities including laboratory space and
facilities; (17) provides oversight and management of the distribution,
accountability, and maintenance of CDC property and equipment including
laboratory property and equipment; (18) advises the Director, NCEZID,
on science, policy and communication matters concerning DHQP activities
and subject areas; (19) provides program and Federal advisory committee
administrative support for HICPAC; (20) serves as a division and agency
resource for systematic evidence review, analysis, and guideline
production for infection prevention and control; and (21) coordinates
infection prevention and control (IPC) content for non-pharmaceutical
interventions across community settings.
Antimicrobial Resistance Coordination and Strategy Unit (HRD12).
(1) oversees the coordination of antimicrobial resistance activities at
CDC to meet national goals; (2) represents CDC in interagency
activities on Antimicrobial Resistance including the President's
Advisory Committee for Combatting Antibiotic Resistant Bacteria; (3)
coordinates with other agencies, state and national governments,
medical societies, and other public and private organizations to
enhance domestic and international antimicrobial resistance prevention
and control, surveillance and response, and applied research; (4)
represents CDC at the Transatlantic Task Force on Antimicrobial
Resistance (AR); (5) oversees CDC AR budget to implement AR activities
as part of the Federal Action Plan to Combat Antibiotic Resistant
Bacteria; (6) coordinates policies and communications of programs
across CDC related to antimicrobial resistance; (7) ensures
coordination with appropriate CIOs and CDC staff offices on AR program
matters including budget formulation and execution; (8) provides
updates and reports about CDC AR activities and progress to CDC
Director, HHS, and the White House; (9) oversees coordination of CDC
collaborations and new Federal initiatives to detect, respond and
prevent antimicrobial resistance; and (10) oversees and coordinates
activities of the Antimicrobial Regional Laboratory Network (ARLN),
including the AR regional labs across CDC and with states and partners
and the Global Antimicrobial Laboratory and Response Network with
countries and international partners.
Immunization Safety Office (CRDB). Assesses the safety of new and
currently available vaccines received by children, adolescents and
adults using a variety of strategies: (1) conducts ongoing surveillance
for the timely detection of possible adverse events following
immunization (AEFI) in collaboration with the Food and Drug
Administration, through implementation and management of the Vaccine
Adverse Event Reporting System, the national reporting system that acts
as an early-warning system to detect health conditions that might be
associated with an immunization; (2) coordinates, further develops,
maintains and directs activities of the Vaccine Safety Datalink (VSD),
a collaborative effort with integrated healthcare organizations able to
perform rapid epidemiologic research on potential causality for AEFI
using the VSD and other data sources, provide national estimates of
incidence of AEFI, and determine background rates of health conditions;
(3) leads the nation in developing biostatistical methods for research
of AEFI using large linked databases and other data sources, and shares
methods for use by other agencies and public and private entities; (4)
conducts clinical research to identify causes of adverse events after
immunization, specific populations susceptible to specific adverse
events, and prevention strategies through the DHQP supported Clinical
Immunization Safety Assessment network, a national network of medical
research centers, and through other research efforts; (5) applies
findings from epidemiologic and clinical studies to develop strategies
for prevention of AEFI; (6) provides global consultation and leadership
for the development, use, and interpretation of vaccine safety
surveillance systems, and for the development of shared definitions of
specific health outcomes through participation in the Brighton
Collaboration and other international organizations; (7) provides data
for action to HHS, the Federal Advisory Committee on Immunization
Practices (ACIP), the FDA's Vaccine and Related Biological Products
Advisory Committee, Health Resources and Services Administration's
Advisory Commission on Childhood Vaccines, and international
collaborators including the WHO Global Advisory Committee on Vaccine
Safety; and (8) provides timely, accurate communication and education
to partners and the public on vaccine safety issues.
Clinical and Environmental Microbiology Branch (CRDC). (1) leads
national laboratory characterization of HAI-related threats in
partnership with state and regional laboratories; (2) provides
comprehensive laboratory support and expertise for investigations of
recognized and emerging pathogens in healthcare settings, such as
methicillin-resistant S. aureus, carbapenem-resistant
Enterobacteriaceae, and Clostridium difficile; (3) provides laboratory
response to outbreaks and emerging threats associated with infections/
antimicrobial resistance and related adverse events throughout the
healthcare delivery system; (4) innovates methodologies determining
environmental contribution to healthcare related outcomes, assesses
environmental hygiene, and develops methods to assess contamination of
environmental surfaces and medical devices; (5) investigates novel and
emerging mechanisms of antimicrobial resistance among targeted
pathogens found in healthcare settings; (6) conducts research in
collaboration with partners to develop new, accurate methods of
detecting antimicrobial resistance in bacteria for early detection of
emerging resistance; (7) conducts laboratory research to identify new
strategies to prevent infections/antimicrobial resistance, related
adverse events, and medical errors, especially those associated with
invasive medical devices, contaminated products, environmental
surfaces, air-handling, dialysis, and water; (8) maintains capacity to
evaluate commercial
[[Page 44324]]
microbial identification and antimicrobial susceptibility testing
systems and products and facilitates their improvement to provide
accurate patient test results; (9) investigates the role of biofilms,
particularly those detected in indwelling medical devices and medical
water systems, in medicine and public health, and identifies novel
methods to eliminate colonization and biofilm formation, including on
medical devices; (10) characterizes and investigates the role of
microbiomes in the prevention of infections and antimicrobial
resistance; (11) investigates the role of the water distribution
systems in healthcare facilities in order to understand and prevent
transmission of healthcare-associated infections due to water, and the
impact of healthcare effluents on surrounding environments and
communities; (12) provides expertise, research opportunities, training,
and laboratory support for investigations of infections and related
adverse events to other CDC centers and to partners in areas related to
quality of clinical microbiology laboratory practices, the
investigation of emerging pathogens, and environmental microbiology;
(13) leads ARLN activities related to healthcare pathogens and provides
assistance to state and regional labs participating in the network;
(14) maintains and manages the Federal AR Isolate Bank, providing
access to curated collections of AR pathogens to academic and industry
partners, including those developing new assays and therapeutics to
address AR threats; (15) integrates epidemiology of healthcare
associated pathogens with molecular genetics and whole genome
sequencing data and bioinformatics to identify, categorize and
attribute pathogens and related genetic elements relevant to healthcare
settings; and (16) assesses, supports and implements use of innovative
technologies and approaches to more accurately and rapidly detect
healthcare-related pathogens and initiate containment of spread.
Prevention and Response Branch (CRDD). Across the healthcare
continuum, including acute, long-term, ambulatory, and chronic care
settings: (1) develops, promotes, and monitors implementation of
evidence-based practices, policies, strategies and related educational
materials to prevent and control HAI and related adverse events
affecting patients and healthcare personnel, associated with antibiotic
resistance, device and procedure associated infections, lapses in
adherence to quality standards and safety, and emerging resistance; (2)
uses data from the NHSN and other sources to target and improve the
prevention and control healthcare-associated infections and
antimicrobial resistance in the United States in specific regions,
settings and institutions; (3) supports local, state, and national
efforts to prevent HAI, antimicrobial resistance, and related adverse
events by providing leadership and technical expertise, including
assessing effectiveness of CDC-recommended prevention practices; (4)
provide leadership and epidemiologic support for the investigation,
monitoring, and control of both recognized and emerging healthcare
pathogens, including antimicrobial resistant bacteria; (5) leads
response and control of outbreaks and emerging threats involving HAI
and related adverse events, contaminated medical products and devices,
and adverse drug events; (6) communicates the results of response
activities with Federal and state agencies, healthcare providers, and
the public, with recommendations to prevent similar adverse events in
the future; (7) provides leadership, guidance, and technical support to
and collaborates with other CDC CIOs, other HHS operating divisions,
and extramural domestic partners, on the epidemiology and prevention
and control of HAI, antimicrobial resistance and related adverse
events; (8) manages and directs the national program supporting state
and local public health agencies to assess and implement activities to
prevent HAIs and antimicrobial resistance in their jurisdictions; and
(9) coordinates production of interim infection control guidance for
emerging infectious threats.
Surveillance Branch (CRDE). (1) monitors and evaluates the extent,
distribution, and impact of healthcare-associated infections,
antimicrobial use and resistance, adverse drug events, healthcare
preparedness/resilience factors and healthcare worker safety events in
the United States through the NHSN, providing data to prevent or
control adverse exposures or outcomes in healthcare; (2) provides
services, including leadership, consultation, and analytic support to
investigators in the branch, division, and other organizations applying
NHSN data to surveillance, research studies, and efforts targeting
prevention and control of HAI and other healthcare-associated adverse
events; (3) works with the Centers for Medicare and Medicaid Services
(CMS) to support CMS payment processes that rely on NHSN data; (4)
partners with CMS and others to develop new metrics and support
maintenance of National Quality Forum-approved metrics; (5)
collaborates with public and private sector partners to further
standardize, integrate, and streamline systems by which healthcare
organizations collect, manage, analyze, report, and respond to data on
HAI, including transmission of multi-drug resistant organisms; (6)
coordinates, further develops, enables wider use, and maintains NHSN to
obtain scientifically valid clinical performance indices that promote
healthcare quality and value at the facility, state, and national
levels; (7) develops and implements new NHSN modules to track and
prevent additional healthcare associated harms; (8) provides
enrollment, security, and user support for over 37,000 NHSN enrolled
facilities; (9) improves surveillance systems by utilizing new
technology; and (10) generates and provides NHSN surveillance reports
and analyses, which include collaborative analytic projects with
partners.
Epidemiology Research and Innovations Branch (CRDG). (1) identifies
and evaluates the efficacy and effectiveness of interventions to
prevent HAI and related adverse events or medical errors across the
spectrum of healthcare delivery sites including acute and long-term
inpatient care, dialysis, and ambulatory settings; (2) identifies gaps
in HAI-related knowledge and conducts prevention research through the
Prevention Epicenters cooperative agreements program and Safety and
Healthcare Epidemiology Prevention Research Development research
contracts; (3) conducts and supports research and evaluates impact of
public health practices to prevent HAIs, antimicrobial resistance,
sepsis and related adverse events; (4) improves methods and enables
wider use of clinical performance measurements by healthcare facilities
and public health entities for specific interventions and prevention
strategies designed to safeguard patients and healthcare workers from
risk exposures and adverse outcomes through collaborations with
extramural partners; (5) conducts applied research to identify and
develop innovative methods, including modeling and economic analyses,
to detect, characterize, monitor, and predict healthcare threats
including HAI, sepsis and antimicrobial resistance; and (6) conducts
special studies to identify and characterize emerging healthcare
threats working with the Emerging Infections Program and other
partners.
Division of High-Consequence Pathogens and Pathology (CRE). The
Division of High-Consequence
[[Page 44325]]
Pathogens and Pathology (DHCPP) maximizes public health and safety
nationally and internationally through the diagnosis, prevention, and
control of disease, disability, and death caused by suspected and known
viral, bacterial, prion, and related infections. In carrying out its
mission, DHCPP: (1) conducts surveillance, investigations, and studies
of viral and bacterial diseases, including bioterrorism agents, as well
as of transmissible spongiform encephalopathies, or prion diseases, and
severe diseases of unknown, but suspected infectious, etiology to
define their etiology and epidemiology, and to develop effective
methods for diagnosis, treatment, control, and prevention; (2) conducts
or participates in clinical, field, and laboratory research to develop,
evaluate, and improve laboratory methods, materials, and therapeutic
practices used for diagnosis, treatment, control, and prevention of
viral, bacterial, and prion diseases, including bioterrorism agents;
(3) conducts research on virus and bacterial transmission to develop
effective control and prevention strategies and on vaccine
effectiveness to assess prevention potential; (4) conducts laboratory,
clinical, and epidemiologic studies of highly hazardous disease agents
that require biosafety level 3 or biosafety level 4 security for their
safe handling; (5) conducts ecological studies to develop and evaluate
disease control and prevention measures; (6) provides epidemic aid,
epidemiologic consultation, reference and diagnostic services, and
technical assistance to state and local health departments, other
Federal agencies, and national and international health organizations;
(7) provides scientific and technical assistance to other CDC
components when the work requires unique expertise or specialized
equipment not available in other components; (8) provides routine and
specialized laboratory training in the diagnosis, isolation, and
characterization of viral and bacterial agents to personnel from state
and local health departments and other national and international
organizations; (9) provides training opportunities for EIS officers and
others in CDC sponsored programs, including postgraduate students,
postdoctoral fellows, and other public health and laboratory
scientists; (10) provides expert pathological support for various
infectious diseases to other groups at CDC, state and local health
departments, and national and international organizations; (11)
provides staffing and support for emergency responses at program,
division, Center, and agency levels; and (12) serves as appropriately
designated national and WHO Collaborating Centers for viral and
bacterial diseases.
Division of Infectious Disease Readiness and Innovation (CRG). The
Division of Infectious Disease Readiness and Innovation (DIDRI) works
to build and strengthen public health capacity and readiness by
enhancing the ability of CDC and its public health partners to prepare
for, prevent, and respond to emerging and reemerging infectious
diseases, including outbreaks, and other public health emergencies,
through cross-cutting and innovative programs, technical expertise, and
public health leadership. In carrying out these activities, DIDRI: (1)
collaborates with state, tribal, local, and territorial (STLT) health
departments, and other external groups for infectious disease programs
and responses to enhance preparedness, and develop innovative responses
to emerging and reemerging infectious diseases with a goal of
increasing capacity of STLT health departments; (2) leads national
wastewater surveillance to understand community-level data on
infectious diseases and other emerging health issues, and facilitates
exchange of data with frontline public health practitioners,
clinicians, decision-makers, key partners, and the public; (3) conducts
innovative surveillance and other public health practices to detect,
control, prevent, and respond to emerging infectious diseases; (4)
supports clinical and public health partners to address health equity
and rapidly respond to infectious diseases and outbreaks; (5) works
with infectious disease programs on processes for developing, awarding,
managing, and evaluating infectious disease grants and cooperative
agreements; (6) provides subject matter expertise for infectious
disease and health informatics; (7) conducts analysis of infectious
diseases using various analytic techniques in coordination with CDC
infectious disease programs; (8) conducts, supports, and evaluates
activities aimed at identifying and reducing risk factors for
infectious diseases overall and among residents of the Arctic and
Subarctic regions; (9) collaborates with public health partners to
identify and eliminate health disparities among Alaska Natives,
American Indians, and indigenous populations; (10) implements the
Advanced Molecular Disease program by integrating advanced molecular
technologies into the public health system to strengthen the prevention
and response to significant public health threats and improve
identification and characterization of various pathogens; (11) provides
cross-cutting infectious disease support for evaluation and modeling to
assess public health impact; (12) establishes integrated and
sustainable laboratory data and systems that are accessible to all
public health organizations; and (13) provides staffing and support for
emergency responses at program, division, Center, and agency levels.
Office of the Director (CRG1). (1) manages, directs, and
coordinates the activities of the division, and advises the NCEZID
Director, NCEZID divisions, and CDC leadership on emerging infectious
disease science, readiness, response, and innovation; (2) provides
leadership and guidance on division policy, communication, program
planning, program management, and operations; (3) provides division-
wide administrative and program services and ensures coordination with
the appropriate CIO or staff offices on administrative and programmatic
matters; (4) partners with Federal agencies, STLT health departments,
international organizations, academic institutions and other external
groups on readiness and innovative responses to emerging and reemerging
infectious diseases; (5) ensures coordination of cross-cutting division
activities with NCEZID divisions, and CDC CIOs; (6) advances health
equity through scientific and programmatic infectious disease
activities; and (7) improves the understanding of factors involved in
infectious disease emergence, prevention, and elimination.
Arctic Investigations Program (CRGB). (1) conducts, supports, and
evaluates activities to improve the health of people of the Arctic and
Subarctic regions, with special emphasis on reducing and preventing
infectious diseases of high incidence and concern among Alaska Natives
and American Indians; (2) collaborates with programs across CDC; local,
state, and tribal partners; the Indian Health Service; and other
national and international partners to reduce, prevent, and respond to
infectious disease threats; (3) ensures public health preparedness and
prevention of infectious diseases by conducting infectious diseases
surveillance, providing and evaluating prevention services, and
conducting targeted epidemiologic and laboratory research; (4) works
with public health partners to identify and eliminate health
disparities among American Indians, Alaska Natives, and other
indigenous populations; and (5) provides leadership to improve health
in the Circumpolar region.
[[Page 44326]]
Division of Core Laboratory Services and Response (CRH). The
mission of the Division of Core Laboratory Services and Response
(DCLSR) is to provide products, services, and specialized expertise to
CDC programs in support of emergency response activities, laboratory
research, and laboratory operations. To carry out its mission, DCLSR:
(1) provides laboratory support to outbreak responses through specimen
accessioning, pre-clinical processing of diagnostic specimens, surge
testing capacity, and long-term sample management, including the CDC
Biorepository; (2) provides laboratory supplies, glassware, mammalian
tissue cultures, microbiological media, special reagents, and other
laboratory materials in support of research and service activities to
laboratories and CDC investigators; (3) promotes animal welfare and
improves the quality and integrity of animal-based research by engaging
in independent and collaborative research, providing state-of-the-art
training to researchers and partners, and offering a broad range of
fully integrated professional veterinary services; (4) works with CDC
pathogen-specific programs in the evaluation of existing and in the
design of innovative and novel diagnostic tests and assays (molecular,
immunological, and sequence based) and evaluation of new instrument
platforms and technologies to detect emerging and known pathogens; (5)
develops and implements applied research programs to expand and enhance
the use of animal models necessary to support research and diagnostic
programs and to improve breeding and husbandry procedures; (6) conducts
applied research in cell biology and in the expansion of tissue culture
technology as a research and diagnostic tool for infectious disease
activities; (7) provides services for laboratory investigators in
protein and DNA synthesis and sequencing, genomic sequencing,
microarrays, proteomics, and molecular modeling; (8) obtains and
distributes experimental and orphaned vaccines, drugs, antisera,
antitoxins, and immune globulins; (9) manages and distributes the
inventory, maintains the computerized system database, and provides
general technical service support for the dispensing, lyophilizing,
capping, and labeling of CDC reference reagents; (10) receives,
triages, processes, and distributes specimens to CDC laboratories for
reference diagnostic testing, research studies, and epidemics and
reports diagnostic test results to submitting organizations; (11)
manages all CDC exports and ensures compliance with regulations and
serves as CDC liaison with the Department of Commerce for export-
related issues; (12) produces and distributes specialized reagents and
diagnostic kits for research and development, surveillance,
preparedness activities, outbreak and emergency response; (13) provides
services and expertise in development of quality systems to support
compliance with FDA regulations on production, distribution, and use of
laboratory diagnostic reagents; (14) provides liaison activities,
resources, and expertise for inquiries related to animals and zoonotic
diseases; (15) provides a centralized activity for tracking requests
for and distributing select agents to investigators outside of CDC in
compliance with Federal regulations; and (16) provides staffing and
support for emergency responses at the program, division, Center, and
agency levels.
Office of the Director (CRH1). (1) manages, directs, and
coordinates the activities of DCLSR; (2) provides leadership and
guidance on the development of strategic goals, objectives, and
milestones to advance the vision and mission of DCLSR; (3) distributes
investigational and licensed drugs and unique biologicals (antitoxins)
to approved physicians for the treatment of rare, tropical, or
exceptional diseases; (4) develops administrative policies, processes,
and operations for the division; (5) ensures that health equity
principles are applied in all DCLSR activities; (6) works to ensure
that spending plans and budgets are executed and aligned with the
strategic priorities of the division; (7) works with NCEZID Office of
the Director to establish and maintain a diverse, equitable, inclusive,
and accessible workplace; (8) provides scientific, business, and policy
oversight and guidance for all programs and activities housed in the
division; and (9) works closely with other CIOs during outbreak
investigations and on an ongoing basis, providing support, guidance,
collaboration, and expertise.
Division of Vector-Borne Diseases (CRJ). (1) conducts surveillance,
investigations, and studies of vector-borne viral, rickettsial, and
bacterial diseases to define disease etiology and to develop effective
methods and strategies for diagnosis, prevention, and control; (2)
conducts investigations on the biology, ecology, and control of
arthropod vectors of viral, rickettsial, and bacterial diseases as a
basis for development of new and/or modification of existing measures
for more effective prevention and control; (3) conducts or participates
in clinical, field, and laboratory studies to develop, evaluate, and
improve laboratory methods, materials, and therapeutic practices used
for diagnosis, prevention, and treatment of vector-borne infectious
diseases; (4) provides epidemic aid and epidemiologic consultation,
upon request, to state and local health departments, other Federal
agencies, and national and international health organizations; (5)
provides reference/diagnostic services for vector-borne viral,
rickettsial, and bacterial diseases to state and local health
departments, other Federal agencies, and national and international
health organizations; (6) conducts research and collaborates on
development and evaluation of vaccines; (7) provides scientific and
technical assistance to other CDC components when the work requires
unique expertise or specialized equipment not available in other
components; (8) provides intramural and extramural technical expertise
and assistance in professional training activities; (9) serves as
designated national and international reference centers for vector-
borne viral, rickettsial, and bacterial diseases; and (10) provides
staffing and support for emergency responses at program, division,
Center, and agency levels.
IV. Under Part C, Section C-B, Organization and Functions, add the
following functional statements:
Travel Risk Assessment and Mitigation Branch (CRCB). (1) supports
and evaluates public health preparedness activities for response to
communicable diseases at airports, seaports, and land crossings in the
United States including establishing accords with hospitals to ensure
adequate isolation and care of persons with certain communicable
diseases; (2) reviews operations to innovate and use scientific methods
to inform more effective surveillance and response activities to
prevent the importation and spread of quarantinable and other
communicable diseases linked to travel from posing a threat to the U.S.
population; (3) establishes partnerships and provides technical
assistance to Federal, state/territorial, industry and international
partners on domestic and international border health issues; (4)
enforces public health authorities and collaborates with state and
local health departments to prevent disease transmission associated
with travel and offers local officials consultation on isolation,
quarantine, and other public health interventions in collaboration with
the Port of Entry Operations Branch; (5) contributes border health
expertise to the transportation sector in the United States, abroad,
and to
[[Page 44327]]
multilateral bodies, including sharing recommendations on public health
risk assessment and management practices, and conducts communications,
media, and training for the Travel Risk Assessment and Mitigation and
the Port of Entry Operations team members; (6) develops content for
websites, videos, and maps to support airport partners and the public
at POE regarding public health threats and Federal regulations
delegated to CDC, including providing guidance to partners that
implement CDC's delegated regulatory authorities at U.S. borders; (7)
provides epidemiological support for activities related to border
health and globally mobile populations including implementation of
analytical projects to build scientific evidence for travel-related
mitigation measures and dissemination of results for public health
action; (8) provides technical consultation and develops public health
training to border health staff and other agencies carrying out Federal
inspections services at POE to enforce HHS/CDC regulations on
quarantine; (9) serves as an identified point of contact with Federal
security agencies when health, travel, and security intersect; and;
(10) provides medical and veterinary-support to Port of Entry
Operations Branch team members to respond to illnesses or HHS/CDC-
regulated animals and other importations at POE.
Immigrant and Refugee Health Branch (CRCC). (1) recommends
appropriate, effective intervention and prevention strategies to
decrease morbidity and mortality among globally mobile populations and
to prevent entry of disease into the United States; (2) implements
enhanced public health interventions for refugees such as vaccination
and presumptive treatment programs for intestinal parasites and
malaria; (3) responds to refugee resettlement health emergencies
overseas and domestically; (4) oversees, evaluates, and monitors the
required overseas and domestic medical examinations of immigrants and
refugees (and others for whom a medical exam is required), and
prepares, publishes, updates, and distributes Technical Instructions
for examining physicians; (5) works cooperatively with state health
departments to form multi-state networks for health surveillance of
refugees and to develop health guidance for health professionals who
care for newly arrived refugees; (6) establishes, maintains, and
evaluates notification procedures regarding immigrants and refugees,
providing coordination and liaison with local and state health
departments on the follow-up of those with serious diseases of public
health significance, in particular notifiable diseases such as
tuberculosis; (7) conducts continuing review, technical guidance, and
evaluation of required immigration medical screening procedures to
ensure the most effective application of current medical practices; (8)
develops and administers training curricula for examining physicians to
support rigorous adherence to the CDC Technical Instructions; (9) works
cooperatively and in concert with other Federal and international
agencies, voluntary agencies, and foreign governments, both in the
United States and abroad, in administering required medical screening
programs for immigrants, refugees, parolees, and non-immigrant visa
applicants; (10) performs epidemiologic investigations and scientific
research projects related to health issues for immigrant, refugee, and
migrant populations; (11) establishes and maintains procedures to
process requests for waivers for applicants with inadmissible medical
conditions; (12) works with foreign governments and partners to
establish or strengthen public health conditions for U.S.-bound
populations, and other globally mobile populations for the prevention,
detection, and response to infectious diseases; (13) provides support
to international government and public health partners to strengthen
global public health capacity to help prevent the spread of infectious
diseases; (14) determines and strategically tracks factors that affect
the health of U.S.-bound or recently arrived refugees, immigrants, and
migrants through research, evaluation, and high-quality data sources
and systems; and (15) educates Federal, state, and private agencies
about health aspects of international child adoption procedures.
Travelers' Health Branch (CRCD). (1) improves the health of all
global travelers, including underserved populations, and prevents the
importation of communicable disease to the United States, the
Travelers' Health Branch (THB) produces travelers' health
recommendations for international travelers, healthcare providers,
employers, and policymakers, (2) produces Travel Health Notices to
inform travelers and other audiences about global health risks during
outbreaks, special events or gatherings, and natural disasters, and
provide advice on protective actions travelers can take to prevent
infection and other adverse health effects; (3) conduct mapping and
spatial representation of outbreak areas and areas where diseases are
endemic; (4) produces the print and online premiere medical textbook on
travel health medicine used by clinicians and other partners; (5)
produces and maintains CDC Travelers' Health website, an online
compendium of travel medicine information and recommendations; (6)
supports surveillance systems for travel-related illness trends and
pathogens through collaborations with national and international travel
clinic networks and the development and evaluation of traveler and
travel conveyance surveillance sampling and testing strategies for
pathogen detection and characterization, (7) translates travel medicine
science into actionable health information recommendations, including
online educational products, and mobile tools; (8) manages a registry
of national providers and yellow fever stamp owners, provides guidance
regarding yellow fever vaccine requirements and recommendations for
international travelers, and conducts ongoing surveillance for serious
adverse events following yellow fever vaccination; (9) participates in
ACIP workgroups regarding vaccines used for travelers and works with
vaccine producers to ensure availability of travel vaccines; (10)
collaborates with private partners to analyze global data on disease
incidence and risk factors among travelers; (11) partners with
international organizations such as the WHO to establish consensus on
travel medicine evidence base, disease-specific data repositories, and
definitions of diseases of relevance to travelers' health; (12)
participates in emergency responses to provide support for traveler
issues including surveillance, traveler health prevention and treatment
recommendations; and (13) performs rapid assessments of available
epidemiological information to develop public health risk assessment
and guidance for travelers.
Port Health Protection Branch (CRCE). As CDC's representative at
U.S. POE for mitigating biosecurity and emerging infections, (1)
protects the public's health at U.S. borders and POE by working with
state and local health departments, ministries of health, the WHO, and
intergovernmental organizations in collaboration with the Travel Risk
Assessment and Mitigation Branch; (2) responds to travel-related
communicable disease threats and develops and implements strategies to
prevent introduction and spread of diseases of public health concern
arriving in persons, animals, cargo, and conveyances at U.S. POE; (3)
documents those activities to provide surveillance
[[Page 44328]]
of public health events occurring at sea, air, and land POE to the
United States and its possessions; (4) provides public health training
to field staff and other on-site agencies carrying out Federal
inspection services at POE to enforce CDC regulations on quarantine,
apply public health best practices, augment CDC's geographic reach at
POE, and ensure appropriate occupational safety and health protection
for their staff; (5) stores and rapidly distributes emergency and
lifesaving medications not otherwise available for patients in the
United States and its possessions from designated POE locations; (6)
provides logistics support to other CDC programs and other partners and
expedites the movement of persons, clinical specimens, and other
materials through Federal security and the rest of the Federal
inspection apparatus; and (7) provides in-person or telephone
consultative response to public health threats at U.S. POE 24 hours a
day and seven days a week with support of Quarantine Medical Officer(s)
and Quarantine Veterinary Officer(s) from the Travel Risk Assessment
and Mitigation Branch for reports of ill travelers, or problems with
animals, biological materials, and other CDC regulated importations.
Southern Border Health and Migration Branch (CRCG). (1) provides
scientific and technical support to the division and agency's
operational and public health regulatory and emergency response
responsibilities concerning infectious diseases among the U.S.-Mexico
and other Latino binational populations and other globally mobile
populations traversing the U.S. southern border, the busiest land
border in the world; (2) focuses on the prevention and control of
infectious diseases and expanding the health evidence base among the
dynamic and globally mobile populations that reside in and travel
through the southern U.S. land border region through activities
including surveillance, illness response, epidemiologic investigations
and analyses, and leveraging strategic partnerships and scientific
collaborations (e.g., other Federal agencies, state and local health
authorities, international and regional organizations, non-governmental
organizations, and health authorities from Mexico and other key migrant
stream countries); (3) supports the division's regulatory activities at
southern U.S. land points of entry including illness response, animal,
biologic and etiologic importations that have infectious disease
implications for human health; (4) expands evidence base and
intervention support for infectious diseases and health disparities
among the populations that reside, work, and travel through the
southern U.S. land border region and other Latino binational
populations in the United States, including Spanish speaking migrants
and farmworkers, through targeted education, linguistically appropriate
health communications, outreach activities, and partnerships; (5)
supports transnational continuity of care and travel restriction
decisions for persons with active tuberculosis moving in or out of the
United States; (6) helps facilitate CDC projects with Mexico (Mexico
Country Office) and the Central American Region (Panama Office) to
address priority health issues of mutual interest that will advance
scientific knowledge, protect binational, regional and migratory
populations, and facilitate coordinated disease response and health
security between the public health officials in the United States,
Mexico, and Central America; and (7) supports binational working
groups, collaborations, and data systems that support surveillance,
information sharing, expand evidence base on health disparities and
control of binational/border communicable diseases of importance, and
support partnerships with key organizations and governmental agencies
to enhance service provision to mobile border/binational populations.
Healthcare Systems Strengthening, Resilience, and Training Branch
(CRDH). (1) leads, in collaboration with the other appropriate division
components, development and delivery of training related to the
prevention of HAIs, antimicrobial resistance, adverse events, and
medical errors, and improving environmental hygiene, use of personal
protective equipment, disinfection, sterilization, and other related
topics with a focus on remote, rural, and underserved areas; (2) builds
and supports partnerships with organizations that increase reach and
impact for DHQP training content; (3) identifies and addresses gaps in
information needed to successfully implement and optimize training and
IPC in healthcare settings; (4) supports state, local, and Federal
efforts to establish and improve infection prevention and control
through training and implementation programs, and policies that support
IPC resilience; (5) assists partners in improving infection prevention
and control, HAI surveillance, and environmental hygiene capacities
through tailored long-term consultative support; (6) provides technical
assistance for development of organization-specific infection control
policies and action plans to prevent HAIs and reduce antimicrobial
resistance; (7) leads healthcare preparedness and resilience planning
and implementation to enable healthcare facilities to respond to
infectious disease threats at local, regional and national levels,
including monitoring and reporting related to acute surges in staffing
and resource needs, impacts on healthcare personnel, bed and equipment
availability, and coordination within local jurisdictions; (8)
coordinates DHQP activities and collaborates with other CIOs and
Federal agencies to prepare healthcare to respond to emerging threats;
(9) represents and coordinates DHQP activities for agency-wide
responses and collaborates with CDC Emergency Operations Center for
emergency response to emerging infections involving healthcare (e.g.,
Ebola); and (10) provides expert consultation, guidance, and technical
support to and collaborates with other CDC CIOs, other HHS operating
divisions.
International Infection Control Branch (CRDJ). (1) leads, in
collaboration with the appropriate CDC CIO and other components, global
health activities related to the prevention of HAIs, antimicrobial
resistance, and related adverse events or medical errors; (2)
coordinates international efforts to establish and improve infection
prevention and control policies, programs, and collaborations; (3)
assists countries to improve infection prevention and control capacity
toward prevention and control of endemic and outbreak-related HAIs
outbreaks; (4) produces tailored implementation and training content to
support countries and international partners working to improve
healthcare safety and quality; (5) in collaboration with ministries of
health, CDC country offices, and implementing partners, develops
country-specific national policies and action plans to improve
healthcare safety and reduce the global burden of antimicrobial
resistance associated with healthcare delivery; (6) provides technical
assistance to international partners in building diagnostic laboratory
capacities and surveillance systems; and (7) leads development of
global networks to detect and contain infectious disease threats
related to healthcare.
Medical Product Safety Branch (CRDK). (1) leads CDC's activities on
blood, organ, and other tissue safety; (2) represents CDC on the
Advisory Committee on Blood Safety and Availability and the Advisory
[[Page 44329]]
Committee on Organ Transplantation; (3) works with other Federal
agencies, state governments, and other public and private organizations
to enhance blood, organ, and other tissue safety through coordination
of investigation, prevention, response, surveillance, applied research,
health communication, and public policy; (4) leads CDC's national
adverse drug events surveillance activities and seeks to translate
population-based ADE surveillance data into evidence-based policies and
targeted, innovative and collaborative interventions; and (5) develops,
promotes, and monitors implementation of and adherence to evidence-
based practices, policies, strategies, and related educational
materials to increase adherence to optimal antimicrobial use and
stewardship across all healthcare settings.
Epidemiology Laboratory Capacity (ELC) and Informatics Branch
(CRGC). (1) builds the capacity of state, local, and territorial public
health agencies to prevent and respond to infectious diseases through
the ELC cooperative agreement; (2) provides scientific and programmatic
guidance, as well as management, administrative, and technical support
for broad infectious disease cooperative agreements such as the ELC
program; (3) serves as a liaison/point of contact to assist recipients
in identifying appropriate technical assistance; (4) provides program
expertise, innovation, and linkages for infectious disease and health
informatics; (5) increases adoption of electronic exchange of public
health data between CDC and frontline public health agencies; and (6)
analyzes the effectiveness and impact of infectious disease activities
in collaboration with other CDC programs with various analytic
techniques.
Rapid Response Research and Surveillance Branch (CRGD). (1)
responds to emerging infectious disease outbreaks and emergencies
through innovation and by collaborating and partnering with STLT public
health agencies and providing scientific technical assistance; (2)
implements wastewater surveillance to provide an early warning for
emerging infections or public health concerns by coordinating and
building wastewater surveillance capacity, and providing real-time,
community-level data to clinicians, decision-makers, key partners, and
the public; (3) leads and supports infectious disease fellowship and
training programs; (4) supports health departments and other clinical
and public health partners on issues related to improving health equity
and infectious disease rapid response activities and resources; (5)
conducts surveillance and other novel and innovative public health
practice activities to detect, control, and prevent emerging infectious
diseases; and (6) creates study activities and related publications
that support public health science and response activities and
interventions.
Office of Advanced Molecular Detection (CRGE). (1) integrates
advanced molecular technologies into the public health system, both
domestically and globally, to enhance the prevention and response to
significant public health threats and improve the identification and
characterization of various pathogens; (2) develops innovative tools
for the detection, characterization, prediction, modeling, and early
recognition of emerging infectious diseases; (3) establishes enhanced,
sustainable, and integrated laboratory data and systems that are
accessible for all public health organizations; (4) builds workforce
capacity in genomic sequencing, bioinformatics, and molecular
epidemiology within public health organizations and in partnership with
the private sector and academia, both domestically and globally; and
(5) leads ongoing quality initiatives for genomic surveillance
throughout CDC, including the infectious disease review board and
quality validation framework.
Advanced Diagnostics and Biotechnologies Branch (CRHB). (1)
provides state-of-the-art next-generation genomic sequencing and
metagenomics analysis of infectious and biothreat agents; (2) provides
optical mapping to produce high resolution whole- genome maps for
strain typing, molecular epidemiology, comparative genomics, and
quality control for whole genome sequence assembly; (3) provides
computational analysis of genomics sequencing data, bioinformatics, and
biological computing; (4) provides qualitative and quantitative
proteomic analyses (identification of expressed proteins by mass
spectrometry); analysis of functionally-relevant post-translational
modifications of proteins; (5) provides mass spectrometry-based
positive identification of bacteria and fungi; (6) provides synthetic
oligonucleotide chemistry in support of development of rapid diagnostic
tests and characterization of pathogens and their hosts; (7) provides
synthetic peptide chemistry in support of studies of immune response
and antigen-antibody interactions; (8) provides biotechnology seminars
and methods evaluation; (9) works with CDC pathogen-specific programs
in the evaluation of new instrument platforms and technologies to
detect emerging and known pathogens and in the evaluation of existing
and in the design of innovative and novel diagnostic tests and assays
(sequence based); (10) provides laboratory equipment design and repair
services to all CDC; and (11) assesses and supports advanced analytical
methodologies for the CDC scientific community.
Preparedness, Response, and Outbreak Services Branch (CRHD). (1)
provides centralized specimen management services for diagnostic,
reference, and outbreak investigations; maintains a bank of biological
specimens of epidemiological significance to CDC's research and
diagnostic activities; manages and tracks systems of specimen
collections; (2) receives, triages, processes, stores, and distributes
specimens to CDC laboratories for reference diagnostic testing,
research studies, and reports diagnostic and surveillance test results
to submitting organizations; (3) provides extracted nucleic acids under
a Clinical Laboratory Improvement Amendments approved workflow that can
be used for sequencing and molecular diagnostics; (4) maintains and
manages the biological laboratory component of the Laboratory Response
Network (LRN); (5) provides LRN strategic guidance, leadership, and
operations support; (6) provides technical input for assay development
for federally managed environmental monitoring systems and guidelines
developed through U.S. government collaborations for the validation and
use of environmental detection devices; (7) develops LRN protocols for
specimen handling and testing for bioterrorism agents; (8) produces and
manages inventory of high-quality reagents available to LRN
laboratories and expedites shipping of products to support emergency
response needs; (9) collaborates with CDC and external partners to
assist in administering proficiency testing programs for critical
agents for LRN member laboratories; (10) evaluates and validates
advanced technology for the identification and characterization of
agents of bioterrorism and other emerging infectious diseases; (11)
works with CDC pathogen-specific programs in the evaluation of existing
and in the design of innovative and novel diagnostic tests and assays
(molecular and immunological); (12) provides laboratory triage
capability at CDC for unknown biological and chemical agents; (13)
produces hybridomas, monoclonal and polycolonal antibodies, and in
vitro diagnostic products for
[[Page 44330]]
diagnostic research purposes, proficiency testing, pandemic
preparedness, outbreak response and surveillance activities; (14)
collaborates with subject matter experts in regulatory compliant
development, production, packaging, storing and distribution of
Biosafety Level 2 (BSL2)/Biosafety Level 3 (BSL3) reagents, select
agents, novel immuno-chemical reagents and reference diagnostic
reagents; (15) provides dispensing, lyophilizing, label production, and
device assembly services; (16) improves the process of bench-top
development and in-house pilot scale production providing immediate
availability for distribution, preventing backorders and streamlining
commercialization; (17) packages and ships infectious substances and
other materials, ensuring compliance with regulations for shipping
clinical specimens, infectious substances, and other materials; (18)
operates the CDC Biorepository as a centralized resource to preserve
CDC's valuable samples and provide ongoing support to CDC programs;
(19) manages sample collections, along with associated information and
data obtained from CDC's public health surveillance, research, and
outbreak responses; (20) serves as the administrator issuing CDC's
required standardized identifiers: the CDC Sample Identifier and CDC
Unique Identified; and (21) provides consultation in all of the above
technical services.
Laboratory Products and Services Branch (CRHE). (1) maintains
laboratory water treatment systems to ensure quality of CDC reagent
grade laboratory water; (2) produces, develops, evaluates, and
distributes custom microbiological and cell culture media, buffers, and
chemical reagent, mammalian, and insect cell cultures; (3) maintains
CDC's Biological Reference Reagent Inventory, mammalian cell line
repository and a serviceable inventory at the DCLSR Continuity of
Operations storage facility; (4) packages and ships infectious
substances and other materials, ensuring compliance with regulations
for shipping clinical specimens, infectious substances, and other
materials; (5) manages all CDC exports and ensures compliance with
regulations and serves as CDC liaison with Department of Commerce for
export-related issues; (6) oversees laboratory waste management; (7)
coordinates laboratory glassware and stockroom operations, consumables;
and (8) provides consultation in all of the above technical services.
Division of Parasitic Diseases and Malaria (CRK). The Division of
Parasitic Diseases and Malaria (DPDM) prevents and controls parasitic
diseases in the United States and throughout the world by providing
diagnostic, consultative, epidemiologic services, and training. In
carrying out its mission, DPDM: (1) conducts surveillance,
investigations, and studies of parasitic diseases to define disease
etiology, mode of transmission, and populations at risk, and to develop
effective methods for diagnosis, prevention, control, and elimination;
(2) conducts or participates in clinical, field, and laboratory
research to develop, evaluate, and improve laboratory methodologies,
materials and therapeutic practices used for rapid and accurate
diagnosis and treatment of parasitic diseases; (3) provides epidemic
aid, epidemiologic consultation, and reference diagnostic services to
state and local health departments, other Federal agencies, and
national and international health organizations; (4) conducts a program
of laboratory and field research in the biology, ecology, and host-
parasitic relationships to develop better methods for diagnosis,
prevention, and control of parasitic diseases; (5) coordinates with the
U.S. Agency for International Development to address neglected tropical
diseases and to achieve the goals of the President's Malaria
Initiative; (6) provides scientific and technical assistance to other
components within CDC when the work requires unique expertise or
specialized equipment not available in other CDC components; (7) serves
as WHO Collaborating Centers for Cysticercosis, Research Training and
Eradication of Dracunculiasis, Control and Elimination of Lymphatic
Filariasis, Evaluating and Testing New Insecticides, Insecticide
Resistance, Insect Vectors; Malaria Control in Africa, Human African
Trypanosomiasis, Production and Distribution of Malaria Sporozoite
enzyme-linked immunosorbent assay; (8) maintains field-based research
and program activities in numerous developing countries; (9) provides
communications support for responsive, evidence-based information
targeted to the public, local and state health officials, international
partners, and private organizations to inform health decisions, to
prevent, and control parasitic diseases in the United States and
abroad; and (10) provides staffing and support for emergency responses
at program, division, Center, and agency levels.
Office of the Director (CRK1). (1) works with NCEZID Office of the
Director to ensure spending plans and budget are in line with the
overall infectious disease strategies and priorities; (2) ensures that
the NCEZID strategy is executed by the division and aligned with
overall CDC goals; (3) co-develops execution strategies for the
division with the branch chiefs; (4) provides program and science
quality oversight; (5) builds leadership at the division and branch
levels; (6) evaluates the strategies, focus, and prioritization of the
division research, program, and budget activities; (7) identifies and
coordinates synergies between the division and relevant partners; (8)
ensures that policy development is consistent and appropriate; (9)
facilitates research and program activities by providing leadership
support; (10) proposes resource priorities throughout the budget cycle;
(11) ensures scientific quality, ethics, and regulatory compliance;
(12) fosters an integrated approach to research, program, and policy
activities; and (13) liaises with HHS and partners.
Malaria Branch (CRKB). (1) conducts malaria surveillance,
prevention, and control in U.S. residents and visitors by monitoring
the frequency and distribution of malaria cases that occur in U.S.
residents and visitors and the efficacy and safety of antimalarial
drugs for chemoprophylaxis and chemotherapy; (2) provides clinical
advice and epidemiologic assistance on the treatment, control, and
prevention of malaria in the United States and in malaria-endemic
countries; (3) provides information to the U.S. public and to
appropriate agencies and groups on appropriate measures to prevent and
control malaria; (4) provides consultation, technical assistance, and
training to malaria-endemic countries and to international and U.S.
agencies and organizations on issues of malaria prevention and control;
(5) conducts epidemiologic, and field-based research projects,
including laboratory and field studies on parasitic diseases to define,
transmission dynamics, populations at risk, and determinants of
morbidity and mortality; (6) conducts field studies of malaria
prevention and control tools and strategies; and (7) conducts
assessments of malaria monitoring and evaluation methods and program
use of these methods.
Parasitic Diseases Branch (CRKC). (1) investigates outbreaks and
unusual occurrences of parasitic diseases in concert with states,
ministries of health, WHO, and other agencies and organizations; (2)
conducts surveillance of parasitic diseases in the United States,
including foodborne parasitic disease outbreaks; (3) provides
consultation on the prevention, treatment, and management of parasitic
diseases to clinicians, laboratorians,
[[Page 44331]]
departments of health, and other agencies; and provides otherwise
unavailable anti-parasitic drugs to healthcare providers and ensures
compliance with FDA's regulations; (4) supports the agency's overall
emergency response mandate; (5) conducts field and laboratory
investigations and research on the etiology, epidemiology, chemotherapy
and other aspects of parasitic diseases to develop new tools for
identifying and controlling parasitic diseases; (6) carries out and
evaluates operational research to evaluate current strategies and
develops new strategies to support programmatic activities for the
control and elimination of parasitic diseases, and provides technical
assistance to ministries of health, WHO, and other agencies and
organizations for these programs; (7) provides training to EIS
officers, Preventive Medicine Residents, public health prevention
specialists, and other fellows and students; and (8) prepares and
disseminates health communication materials on the prevention and
treatment of parasitic diseases.
Entomology Branch (CRKD). (1) conducts global surveillance, field
investigations, and laboratory studies on the vectors of parasitic
diseases of humans, with a focus on malaria, Chagas' disease, lymphatic
filariasis, onchocerciasis, and leishmaniasis, with a particular
emphasis on the anopheline vectors of malaria; (2) serves as WHO
Collaborating Centers for pesticides resistance, anopheline vector
identification, antimalarial drug evaluation, and vector control; (3)
develops methods supporting the global use of pesticides for control of
vector-borne diseases, the management of insecticide resistance, and
the monitoring of anti-parasitic drugs; (4) serves as an international
reference reagent and anopheline vector repository, providing
materials, training, and information related to malaria vectors; and
(5) provides entomological consultation, epidemic aid, and training to
local, state, Federal and foreign agencies and international health
organizations on surveillance and control of malaria and parasitic
vector-borne diseases.
Laboratory Science and Diagnostics Branch (CRKE). (1) provides
reference and laboratory diagnostic services to physicians and
laboratories; (2) transfers technologies and expertise in laboratory
diagnosis of parasitic infections to public health laboratories; (3)
supports the agency's overall emergency response mandate; (4) conducts
field and laboratory investigations and research on the biology,
ecology, pathogenesis, immunology, genetics, host-parasite
relationships, and other aspects of parasitic diseases to develop new
tools for identifying and controlling parasitic diseases; (5) develops
and tests new laboratory methods and tools for improved diagnosis,
control, and prevention of parasitic diseases, and conducts laboratory
training courses for public health laboratories; (6) conducts
laboratory, and field-based research projects, including laboratory and
field studies on parasitic diseases to define biology, ecology,
parasite species differences, host-parasite relationships, diagnostics,
host immune responses; (7) conducts laboratory studies of malaria
parasites utilizing animal models and in vitro systems for parasitic
relationships, chemotherapy, and vaccine evaluation studies; efficacy
and safety of antimalarial drugs for chemoprophylaxis and chemotherapy;
and training to malaria-endemic countries; conducts assessments of
malaria monitoring and evaluation methods; and (8) provides training to
Emerging Infectious Disease fellows, American Society of Microbiology/
Postdoctoral Fellows, and other fellows and students.
V. Under Part C, Section C-B, Organization and Functions, the
following organizational unit is deleted in its entirety:
<bullet> Food Safety Office (CVLB13)
<bullet> Quarantine and Border Health Services Branch (CVLCB)
<bullet> Immigrant, Refugee, and Migrant Health Branch (CVLCC)
<bullet> Geographic Medicine and Health Promotion Branch (CVLCD)
<bullet> International Infection Control Activity (CVLD14)
<bullet> One Health Office (CVLE13)
<bullet> Scientific Programs and Development Branch (CVLGC)
<bullet> Emergency Preparedness and Response Branch (CVLGD)
<bullet> Laboratory Preparedness and Response Branch (CVLGG)
<bullet> Biotechnology Core Facility Branch (CVLHD)
<bullet> Reagent and Diagnostic Services Branch (CVLHG)
Delegations of Authority
All delegations and redelegations of authority made to officials
and employees of affected organizational components will continue in
them or their successors pending further redelegation, provided they
are consistent with this reorganization.
(Authority: 44 U.S.C. 3101)
Robin D. Bailey, Jr.,
Chief Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2023-14704 Filed 7-11-23; 8:45 am]
BILLING CODE 4163-18-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on July 12, 2023.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.